阅读说明：本技术 PGK1靶向siRNA干扰库及其应用 (PGK1 targeted siRNA interference library and application thereof ) 是由 胡宝英 王小林 高明德 沈爱国 于 2021-08-10 设计创作，主要内容包括：本发明公开了PGK1靶向siRNA干扰库及其应用,属于生物工程技术领域。本发明基于膀胱癌细胞存在异常的能量代谢的特点和治疗难点,通过抗膀胱癌基因治疗途径公开了一种PGK1靶向siRNA干扰库在膀胱癌的应用,并提供了该干扰库的三组siRNA核酸序列。细胞学实验表明此siRNA干扰库具有抑制膀胱癌细胞PGK1的蛋白表达和抑制癌细胞存活和增殖等重要功能。本发明为膀胱癌治疗提供了新的药物,对于膀胱癌的临床治疗及其靶向药物开发具有十分重要的应用价值。(The invention discloses a PGK1 targeted siRNA interference library and application thereof, belonging to the technical field of biological engineering. The invention discloses application of a PGK1 targeted siRNA interference library in bladder cancer through an anti-bladder cancer gene therapy approach based on the characteristic of abnormal energy metabolism of bladder cancer cells and treatment difficulty, and provides three groups of siRNA nucleic acid sequences of the interference library. Cytological experiments show that the siRNA interference library has important functions of inhibiting protein expression of bladder cancer cell PGK1, inhibiting cancer cell survival and proliferation and the like. The invention provides a new medicine for treating bladder cancer, and has very important application value for clinical treatment of bladder cancer and development of targeted medicines thereof.)

The PGK1 targeted siRNA interference library is characterized by consisting of three groups of siRNAs, and the specific sequences of the three groups of siRNAs are as follows:

(1)5′-AGGAAGAAGGGAAGGGAAATT-3′，

5′-UUUCCCUUCCCUUCUUCCUTT-3′：

(2)5′-ACAAACAACCAGAGGAUUATT-3′，

5′-UAAUCCUCUGGUUGUUUGUTT-3′；

(3)5′-ACAGAAGGCUGGUGGGUUUTT-3′，

5′-AAACCCACCAGCCUUCUGUTT-3′。

2. the use of the PGK1 targeted siRNA interfering library of claim 1 in the preparation of an anti-bladder cancer medicament.

3. The use of claim 2, wherein the anti-bladder cancer medicament comprises a medicament that inhibits bladder cancer cell proliferation.

4. The use of claim 2, wherein the anti-bladder cancer drug comprises a drug that inhibits glucose uptake by bladder cancer cells.

5. The use of claim 2, wherein the anti-bladder cancer medicament comprises a medicament that inhibits the activity of lactate dehydrogenase in bladder cancer cells.

6. The use of claim 2, wherein the anti-bladder cancer agent comprises an agent that inhibits epithelial-to-mesenchymal transition phenomena of bladder cancer cells.

7. The anti-bladder cancer drug is characterized by comprising a PGK1 targeted siRNA interference library, wherein the PGKl targeted siRNA interference library consists of three groups of siRNAs, and the specific sequence is as follows:

(1)5′-AGGAAGAAGGGAAGGGAAATT-3′，

5′-UUUCCCUUCCCUUCUUCCUTT-3′；

(2)5′-ACAAACAACCAGAGGAUUATT-3′，

5′-UAAUCCUCUGGUUGUUUGUTT-3′：

(3)5′-ACAGAAGGCUGGUGGGUUUTT-3′，

5′-AAACCCACCAGCCUUCUGUTT-3′。

Technical Field

The invention belongs to the technical field of biological engineering, and particularly relates to a PGK1 targeted siRNA interference library and application thereof.

Background

Bladder cancer is the second most common urogenital malignancy, with nearly 90% of primary bladder cancers being caused by the urothelium. 70-80% of urothelial tumors appear superficial (Ta, T1), with the remainder appearing as muscle infiltrates (T2-4) or metastases.

During the bladder cancer progression, the expression of certain genes changes, which are key genes for the development of bladder cancer and become potential targets for the treatment of bladder cancer. Many studies indicate that phosphoglycerate kinase PGK1 is a key enzyme in glycolysis process, and can catalyze ATP to generate higher glycolysis rate, so that energy metabolism of tumor cells is abnormal, and tumor growth is finally promoted. The research findings suggest that the compound has good application prospect as a drug treatment target.

Glycolytic metabolic abnormalities are closely related to tumor metastasis. During the metastasis of tumor, the microenvironment in the tissue is changed to promote the tumor cells to break through the tissue barrier, enter lymph or blood circulation and then metastasize to the distant tissue. Glycolytic metabolic abnormalities can provide a number of metabolites, such as lactate and glutamine, directly or indirectly, to promote tumor metastasis. In addition, an intermediate product produced by glycolytic abnormality, such as acetyl-CoA, can affect the epigenetic inheritance of the cell, promote epithelial-mesenchymal transition of the cell, and convert the cell from a highly adhesive epithelial form to a metastasized mesenchymal form. In the epithelial-mesenchymal transformation process, the expression of epithelial markers on the cell surface, such as E-cadherin, is reduced, and mesenchymal markers, such as N-cadherin, beta-catenin and Vimentin, and related regulatory factors, such as Snail, Twist and p-AKT, are up-regulated, so that morphological changes of cells are induced, and tumors are promoted. Therefore, inhibition of epithelial-mesenchymal transition of tumor cells by intervention of glycolytic metabolic abnormalities is an effective strategy for tumor therapy.

Disclosure of Invention

In view of the above problems in the prior art, the technical problem to be solved by the present invention is to provide a siRNA interfering library, which inhibits the proliferation of bladder cancer cells by siRNA interference. Another objective of the invention is to provide application of the siRNA interference library.

In order to solve the technical problems, the technical scheme adopted by the invention is as follows:

PGK1 targeted siRNA interfering pool consisting of three groups of sirnas with specific sequences as follows:

(1)5′-AGGAAGAAGGGAAGGGAAATT-3′，

5′-UUUCCCUUCCCUUCUUCCUTT-3′：

(2)5′-ACAAACAACCAGAGGAUUATT-3′，

5′-UAAUCCUCUGGUUGUUUGUTT-3′；

(3)5′-ACAGAAGGCUGGUGGGUUUTT-3′，

5′-AAACCCACCAGCCUUCUGUTT-3′。

the PGK1 targeted siRNA interference library is applied to the preparation of anti-bladder cancer drugs.

Further, in the use, the anti-bladder cancer drug comprises a drug for inhibiting the proliferation of bladder cancer cells.

Further, in the application, the anti-bladder cancer drugs comprise drugs for inhibiting glucose uptake of bladder cancer cells.

Further, in the use, the anti-bladder cancer drug includes a drug which inhibits the activity of lactate dehydrogenase of bladder cancer cells.

Further, in the application, the anti-bladder cancer medicament comprises a medicament for inhibiting the phenomenon of bladder cancer cell epithelial-mesenchymal transition.

An anti-bladder cancer drug contains a PGK1 targeted siRNA interference library, wherein the PGK1 targeted siRNA interference library consists of three groups of siRNAs, and the specific sequence is as follows:

(1)5′-AGGAAGAAGGGAAGGGAAATT-3′，

5′-UUUCCCUUCCCUUCUUCCUTT-3′；

(2)5′-ACAAACAACCAGAGGAUUATT-3′，

5′-UAAUCCUCUGGUUGUUUGUTT-3′；

(3)5′-ACAGAAGGCUGGUGGGUUUTT-3′，

5′-AAACCCACCAGCCUUCUGUTT-3′。

compared with the prior art, the invention has the beneficial effects that:

the invention discloses a PGK1 targeted siRNA interference library and application thereof, belonging to the technical field of biological engineering. The invention discloses application of a PGK1 targeted siRNA interference library in bladder cancer resistance through an anti-bladder cancer gene therapy approach based on the characteristic of abnormal energy metabolism of bladder cancer cells and treatment difficulty, and provides three groups of siRNA nucleic acid sequences of the interference library. The siRNA interference library overcomes the problems of single PGK1 targeted siRNA off-target effect, unstable interference efficiency and the like, and can achieve more effective and stable interference inhibition effect on PGK1 in bladder cancer cells. Cytological experiments show that the siRNA interference library has the functions of inhibiting the protein expression of the bladder cancer cell PGK1, inhibiting the survival and proliferation of cancer cells, antagonizing the epithelial-mesenchymal transition of the cancer cells and the like. The invention provides a new medicine for treating bladder cancer, and has very important application value for clinical treatment of tumor and development of targeted medicine.

Drawings

FIG. 1 is a graph of the results of PGK1 expression following transfection of bladder cancer cells with fragments from a small interference pool;

FIG. 2 is a graph comparing the growth of small interfering pool transfected bladder cancer cells with a control group;

FIG. 3 is a graph of the number of cells in different division periods in transfected bladder cancer cells with the small interference pool and a control group, wherein, the graph A is a flow cytometry of transfected bladder cancer cells with the control group, the graph B is a flow cytometry of transfected bladder cancer cells with the small interference pool, and the graph C is a statistical comparison graph of the number of cells in different division periods in the graph A and the graph B;

FIG. 4 is a graph comparing the glucose content of small interfering pool transfected bladder cancer cells with that of a control group;

FIG. 5 is a graph comparing the lactate concentration in small interfering pool transfected bladder cancer cells with that in a control group;

FIG. 6 is a graph comparing the expression of small interfering pool transfected bladder cancer cells with the epithelial-mesenchymal transition markers of a control group.

Detailed Description

The invention is further described with reference to specific examples.

Example 1:

the first step is as follows:

the specific sequences of three siRNAs consisting of PGK1 targeted siRNA interference libraries are as follows,

si-PGK1：

(1)5′-AGGAAGAAGGGAAGGGAAATT-3′，

5′-UUUCCCUUCCCUUCUUCCUTT-3′；

(2)5′-ACAAACAACCAGAGGAUUATT-3′，

5′-UAAUCCUCUGGUUGUUUGUTT-3′；

(3)5′-ACAGAAGGCUGGUGGGUUUTT-3′，

5′-AAACCCACCAGCCUUCUGUTT-3′；

control group siRNA sequence (negative control sequence):

5′-UUCUCCGAACGUGUCACGUTT-3′，

5′-ACGUGACACGUUCGGAGAATT-3′。

and (3) respectively transfecting the fragments in the small interference library and the siRNA sequence of the control group into a bladder cancer cell strain T24, changing the liquid 12h later, turning the liquid the third day later, collecting a cell sample, and analyzing the expression of PGK1 by using an immunoblotting experiment. As shown in FIG. 1, the expression level of PGK1 protein in the cells transfected with negative control siRNA sequence by control group Con-si was significantly higher than that in the cells transfected with siRNA from small interfering pool.

The second step is that: PGK1 targeted siRNA interfering with the library to inhibit bladder cancer survival and proliferation

1. CCK8 experiment proves that PGK1 targets the anti-tumor survival effect of siRNA interference library

The bladder cancer cells T24 and UMUC3 are respectively inoculated on a 96-well culture plate at the density of 2000 cells/well, the PGK1 targeted siRNA interference library fragments and control group siRNA sequences are transiently transfected on the T24 and UMUC3 cells by using transfection reagents, 10 mu l of CCK-8 solution is added into each well after 0h, 24h, 48h, 72h and 96h respectively, after 2h, the wavelength is 450nm, the light absorption value of each well at different time points is measured on an enzyme linked immunosorbent assay instrument, and the result is recorded. The magnitude of the absorbance reflects the cell activity and is plotted against time as abscissa and absorbance as ordinate based on experimental data. The CCK-8 results showed that the small interfering pool experimental group significantly inhibited proliferation of T24 and UMUC3 cells compared to the control group, as shown in fig. 2.

2. PI staining flow cytometry periodic experiment proves that the anti-tumor proliferation effect of PGK1 targeting siRNA interference library

Bladder cancer cells T24 were seeded at 20000 cells/well in 6-well culture plates, and cells of T24 and UMUC3 were transiently transfected with PGK1 small interfering fragments and other controls using transfection reagents and harvested for 3 days. Resuspend wash 3 times with pre-cooled cell PBS, centrifuge, discard PBS, resuspend with pre-cooled 70% ethanol, place at-20 ℃ for at least 24h to fix. Prior to assay, cells were harvested by centrifugation, ethanol removed, washed 3 times with cellular PBS, and permeabilized with 200 μ L of PBS containing 1% Triton X-100. Then, 300. mu.L of RNaseA was added and the mixture was treated with light at 4 ℃. Then 200. mu.L of PI dye was added, protected from light at 4 ℃ for 20 min. Finally, the PI dye was removed by washing with PBS and detected on a flow cytometer. The results are shown in FIG. 3: compared with a control group, T24 cells in the small interference library experimental group are mainly blocked at the G2 stage, which shows that the si-PGK1 interference library can obviously inhibit the cell cycle process of T24.

The third step: PGK1 targeted siRNA interference library for inhibiting metabolic function of bladder cancer

1. Glucose concentration detection experiment

1) Culturing the bladder cancer cell line T24 into a control siRNA group (Con-si) and a siRNA interference library group (si-PGK1) of PGK1, collecting cells into a centrifugal tube after 3 days, centrifuging and removing supernatant;

2) cells were collected by centrifugation at 10 cell counts⁶The volume of the required lysate is 0.1mL, and the lysate is kept stand for 10 minutes at room temperature after shaking and cracking;

3) adding lysis solutions of a glucose standard, a Con-si group and a si-PGK1 group into a 96-well plate, making 3 multiple wells for each group, and adding working solution (8 mL of reagent R1 is mixed with 2mL of reagent R2 to obtain 10mL of working solution for use on the same day) in a histiocyte glucose oxidase method determination kit (abs 47047405) according to the proportion shown in the table.

4) The above 96-well plate was reacted at 37 ℃ for 20 min.

5) Detecting the OD value of each hole with the wavelength of 490nm of an enzyme-labeling instrument

6) Glucose concentration (mmol/L) ═ standard concentration — (sample tube OD-blank tube OD)/(standard tube OD-blank tube OD).

The results are shown in FIG. 4, the siRNA interference library of PGK1 infected the bladder cancer cell line T24 can significantly inhibit the glucose uptake of cancer cells.

2. Lactate dehydrogenase Activity detection experiment

1) Culturing the bladder cancer cell line T24 into siRNA interference library groups (si-PGK1) of control siRNA group (Con-si) and PGK1, repeating the steps for 3 times or more, and collecting cell culture supernatant for 3 days;

2) the corresponding reagents were added in the recommended proportions in the lactic acid test kit (Nanjing Kogyo, A019-2-1) as shown in the following table:

3) using standard tubes (1mmol/L, 2mmol/L, 3mmol/L, 4mmol/L, 5mmol/L, 6mmol/L) of various concentrations of lactic acid and the measured OD values, a standard curve of lactic acid was plotted, and the equation of the standard curve was calculated.

4) And calculating the lactic acid concentration of the Con-si group and the si-PGK1 group of the samples to be tested by using the standard curve.

As a result, as shown in FIG. 5, infection of the bladder cancer cell line T24 with siRNA interfering pool of PGK1 can significantly inhibit the lactate dehydrogenase activity.

The fourth step: PGK1 targeting siRNA interference library inhibits cell epithelial-mesenchymal transition marker expression

1) Culturing the bladder cancer cell line T24 to respectively transfect a control siRNA group (Con-si) and a siRNA interference library group (si-PGK1) of PGK1, collecting cells into a centrifugal tube after 3 days of transfection, centrifuging and then removing supernatant;

2) the cells were incubated on ice for 30 minutes using an appropriate amount of RIPA cell lysate (50mM Tris-Cl pH 8.0, 150mM NaCl, 0.5% Sodium deoxyholate, 0.1% SDS, 1 × protease inhibitor), followed by centrifugation at 13000g for 15 minutes at 4 ℃ and collection of the supernatant lysate;

3) the supernatant lysates were used to quantitate the protein concentration in the Con-si and si-PGK1 groups using Bio-Rad BCA protein quantitation method. The method comprises the following steps: uniformly mixing the solution A and the solution B in the BCA kit according to the ratio of 50: 1, adding the mixture into a 96-well plate at a rate of 200 mu L/well, then adding 10 mu L of 2mg/mL protein standard or 2.5 mu L of supernatant of Con-si and si-PGK1 groups, incubating for 30 minutes at 37 ℃, detecting the absorbance at 595nm in a microplate reader, calculating the protein concentration in each group by using linear regression, diluting the protein sample to 2 mu g/mu L by using SDS loading buffer, and boiling for 5 minutes in boiling water;

4) loading the sample into 10% SDS-PAGE gel electrophoresis, separating the protein sample under the condition of 100V, and transferring the membrane sample into a PVDF membrane by using a Bio-Rad protein transfer membrane system after the separation is finished;

5) the transferred PVDF membrane was blocked with a TBST solution containing 5% skim milk (20mM Tris-C1 pH 7.6, 150mM NaCl, 0.05% Tween-20) for 1 minute, followed by overnight incubation of the membrane with antibodies to each epithelial mesenchymal marker;

6) after the incubation is finished, washing the PVDF membrane by using a TBST solution for 3 times, 5 minutes each time, then incubating the PVDF membrane with a secondary antibody marked by HRP, and after the incubation is finished, washing the PVDF membrane by using the TBST solution for 3 times, 5 minutes each time;

7) the PVDF membrane is incubated by using an enhanced chemofluorescence substrate, and the strip signals of various epithelial mesenchymal markers are developed by using a film for analysis.

As shown in FIG. 6, compared with the control group, the expression of the epithelial marker E-cadherin on the cell surface of the bladder cancer cell line T24 infected with the siRNA interfering library of PGK1 is up-regulated, and the down-regulation of the mesenchymal markers N-cadherin, Vimentin and related regulatory factors such as Twist and p-AKT occur, which indicates that the interfering library can obviously antagonize the epithelial-mesenchymal transition function of the cancer cells.

Sequence listing

<110> university of southeast Tong

<120> PGK1 targeted siRNA interference library and application thereof

<130> 100

<160> 6

<170> SIPOSequenceListing 1.0

<210> 1

<211> 19

<212> RNA

<213> si-PGK1-1-F(Artificial)

<400> 1

aggaagaagg gaagggaaa 19

<210> 2

<211> 19

<212> RNA

<213> si-PGK1-1-R(Artificial)

<400> 2

uuucccuucc cuucuuccu 19

<210> 3

<211> 19

<212> RNA

<213> si-PGK1-2-F(Artificial)

<400> 3

acaaacaacc agaggauua 19

<210> 4

<211> 19

<212> RNA

<213> si-PGK1-2-R(Artificial)

<400> 4

uaauccucug guuguuugu 19

<210> 5

<211> 19

<212> RNA

<213> si-PGK1-3-F(Artificial)

<400> 5

acagaaggcu gguggguuu 19

<210> 6

<211> 19

<212> RNA

<213> si-PGK1-3-R(Artificial)

<400> 6

aaacccacca gccuucugu 19